Skip to main content

Advertisement

SpringerLink
Log in

Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users

  • Original Research
  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil. Economic, socio-demographic, anthropometric, biochemical, and hormonal variables were compared. The EuroQoL Five-Dimension Scale (EQ-5D) was used to evaluate quality of life, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ2 test and Student’s t test, with a significance level of 5 %.The household incomes of approximately 80 % of patients were <2.0 minimum wages ($678). Anthropometric variables (waist circumference, hip circumference, weight, waist-to-hip ratio) and systolic and diastolic blood pressure were noted among male olanzapine users (all p < 0.05). EQ-5D scores showed that olanzapine use significantly impacted self-help ability (p < 0.001). Risperidone users had a mean quality-adjusted life year value of 1. Mean total Simpson–Angus Scale scores was 0.38 for olanzapine users and 0.11 for risperidone users (p < 0.02). Significant differences in UKU were observed for the following items: asthenia/lassitude/fatigue (higher among olanzapine users, p = 0.02), dystonia (higher among olanzapine users, p = 0.01), tremors (higher among olanzapine users, p = 0.03), gynecomastia (higher among risperidone users, p < 0.02), and ejaculatory dysfunction (higher among risperidone users, p < 0.02). Olanzapine users had impaired quality of life, which can be explained in part by adverse motor, biochemical, and hormonal effects characteristic of metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. De Risio A, Lang AP: History and therapeutic rationale of long acting antipsychotics. Current Clinical Pharmacology 9(1):39–52, 2014.

    Article  PubMed  Google Scholar 

  2. Graeff FG, Guimarães FS: Medicamentos Antipsicóticos. Fundamentos de Psicofarmacologia São Paulo: 1999.

  3. Lehmann HE, Ban TA: The history of the psychopharmacology of schizophrenia. Canadian Journal of Psychiatry 42(2):152–162, 1997.

    CAS  Google Scholar 

  4. Mathews M, Muzina DJ: Atypical antipsychotics: New drugs, new challenges. Cleveland Clinic Journal of Medicine 74(8):597–606, 2007.

    Article  Google Scholar 

  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry 13(1):27–35, 2008. doi:10.1038/sj.mp.40020661.

    Article  CAS  PubMed  Google Scholar 

  6. Paredes RM, Quinones M, Marballi K, Gao XL, Valdez C, Ahuja SS et al.: Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. International Journal of Neuropsychopharmacology 17(8):1139–1148, 2014. doi:10.1017/S1461145714000157.

    Article  CAS  Google Scholar 

  7. Arango C, Giraldez M, Merchan-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA et al.: Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naive patients. Journal of the American Academy of Child and Adolescent Psychiatry 53(11):1179–1190, 2014. doi:10.1016/j.jaac.2014.08.009.

    Article  PubMed  Google Scholar 

  8. Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C: Antipsychotic-drug-induced hyperprolactinemia: Physiopathology, clinical features and guidance. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique 40(1):86–94, 2014. doi:10.1016/j.encep.2012.03.002.

    CAS  Google Scholar 

  9. de Araujo AA, Dantas DD, do Nascimento GG, Ribeiro SB, Chaves KM, Silva VD, et al.: Quality of life in patients with schizophrenia: The impact of socio-economic factors and adverse effects of atypical antipsychotics drugs. Psychiatric Quarterly 85(3):357–367, 2014. doi:10.1007/s11126-014-9290-x.

    Article  Google Scholar 

  10. Chaves KM, Serrano-Blanco A, Ribeiro SB, Soares LA, Guerra GC, do Socorro Costa Feitosa Alves M, et al.: Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. The Psychiatric Quarterly 84(1):125–135, 2013. doi:10.1007/s11126-012-9233-3.

    Article  PubMed  Google Scholar 

  11. Manual Diagnóstico e Estatístico de Transtornos Mentais—DSM-IV-TR-TM. ArtMed Porto Alegre, 2003.

  12. Human D: Declaration of Helsinki. Lancet 357(9251):236, 2001. doi:10.1016/S0140-6736(05)71342-8.

    Article  CAS  PubMed  Google Scholar 

  13. Kummerow FA: Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Journal of the American College of Nutrition 12(1):2–13, 1993.

    Article  CAS  PubMed  Google Scholar 

  14. Sposito AC, Caramelli B, Fonseca FAH, Bertolami MC, Afiune Neto A, Souza AD, et al.: IV Diretriz Brasileira sobre Dislipidemias e Prevenção da Aterosclerose: Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros de Cardiologia 88:2–19, 2007.

    Article  PubMed  Google Scholar 

  15. Pinto EB, Maso I, Vilela RNR, Santos LC, Oliveira-Filho J: Validation of the EuroQol quality of life questionnaire on stroke victims. Arquivos de Neuro-Psiquiatria 69:320–323, 2011.

    Article  PubMed  Google Scholar 

  16. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334:1–100, 1987.

    Article  CAS  PubMed  Google Scholar 

  17. Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurology 5(1):5, 2005, doi:10.1186/1471-2377-5-5.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Louza Neto MR: Escalas de avaliacao de efeitos colaterais de antipsicoticos; Rating scales of side effects of antipsychotics. Rev Psiquiatr Clín 25(6):357–367, 1998.

    Google Scholar 

  19. Valadares FC: Desafios políticos da reforma psiquiátrica brasileira. Ciencia & Saude Coletiva 18:573–574, 2013.

    Article  Google Scholar 

  20. Costa JAS, Andrade KVFD: Perfil dos usuários incluídos no protocolo de esquizofrenia em um programa de medicamentos do componente especializado da assistência farmacêutica Profile of patients included in the protocol of schizophrenia in a drug program from specialized component of pharmaceutical assistance Perfil de los usuarios incluidos en el protocolo de esquizofrenia en um programa de medicinas del componente especializado de la asistencia farmacéutica. Rev Baiana Saúde Pública 35(2), 2011.

  21. Saúde Md. PORTARIA N° 364, DE 9 DE ABRIL DE 2013: Aprova o Protocolo Clínico e Diretrizes Terapêuticas - Esquizofrenia. In: Saúde SdAà, editor. Brasília 2013.

  22. Diretriz I: Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arquivos Brasileiros de Cardiologia 84:3–28, 2005.

    Google Scholar 

  23. Salviato Balbao M, Cecilio Hallak JE, Arcoverde Nunes E, Homem de Mello M, Triffoni-Melo Ade T, Ferreira FI, et al.: Olanzapine, weight change and metabolic effects: A naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology 4(1):30–36, 2014, doi:10.1177/2045125313507738.

    Article  Google Scholar 

  24. Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS. Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. International Journal of Neuropsychopharmacology 16(5):987–995, 2013 doi:10.1017/S1461145712001241.

    Article  CAS  PubMed  Google Scholar 

  25. Shoja Shafti S, Gilanipoor MA: Comparative Study between ola1nzapine and risperidone in the management of schizophrenia. Schizophrenia Research and Treatment 2014:307202, 2014. doi:10.1155/2014/307202.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Postgraduate Programs in Public Health and Pharmaceutical Science, Department of Biophysics and Pharmacology, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil

    Aurigena Antunes de Araújo

  2. Postgraduate Program in Pharmaceutical Science, UFRN, Natal, RN, Brazil

    Susana Barbosa Ribeiro & Ana Cely Souza dos Santos

  3. Postgraduate Programs in Health Science and Pharmaceutical Science, Department of Clinical Analyses and Toxicological, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil

    Telma Maria Araújo Moura Lemos

  4. Postgraduate Program in Health and Society, Department of Biophysics and Pharmacology, State University of Rio Grande Norte (UERN), Natal, RN, Brazil

    Caroline Addison Xavier Medeiros

  5. Postgraduate Programs in Biological Science, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil

    Caroline Addison Xavier Medeiros

  6. Department of Biophysics and Pharmacology, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil

    Gerlane Coelho Bernardo Guerra

  7. Postgraduate Program in Functional & Structural Biology and Health Science, Department of Morphology, UFRN, Natal, RN, Brazil

    Raimundo Fernandes de Araújo Júnior

  8. Acute Inpatient Unit of Psychiatry, Parc Sanitari Sant Joan de Deu, Barcelona, Spain

    Antoni Serrano-Blanco

  9. Research and Innovation Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain

    Maria Rubio-Valera

Authors
  1. Aurigena Antunes de Araújo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susana Barbosa Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Cely Souza dos Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Telma Maria Araújo Moura Lemos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Caroline Addison Xavier Medeiros
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerlane Coelho Bernardo Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Raimundo Fernandes de Araújo Júnior
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antoni Serrano-Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria Rubio-Valera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aurigena Antunes de Araújo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Araújo, A.A., Ribeiro, S.B., dos Santos, A.C.S. et al. Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users. Psychiatr Q 87, 293–304 (2016). https://doi.org/10.1007/s11126-015-9385-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-015-9385-z

Keywords

Search

Navigation